- Home
- MIRM vs CELC Comparison
MIRM vs CELC Comparison
Compare MIRM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- CELC
- Stock Information
- Founded
- MIRM 2018
- CELC 2011
- Country
- MIRM United States
- CELC United States
- Employees
- MIRM N/A
- CELC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- MIRM Health Care
- CELC Health Care
- Exchange
- MIRM Nasdaq
- CELC Nasdaq
- Market Cap
- MIRM 3.7B
- CELC 3.1B
- IPO Year
- MIRM 2019
- CELC 2017
- Fundamental
- Price
- MIRM $70.45
- CELC $99.89
- Analyst Decision
- MIRM Strong Buy
- CELC Strong Buy
- Analyst Count
- MIRM 11
- CELC 7
- Target Price
- MIRM $82.82
- CELC $95.29
- AVG Volume (30 Days)
- MIRM 596.2K
- CELC 916.2K
- Earning Date
- MIRM 11-04-2025
- CELC 11-12-2025
- Dividend Yield
- MIRM N/A
- CELC N/A
- EPS Growth
- MIRM N/A
- CELC N/A
- EPS
- MIRM N/A
- CELC N/A
- Revenue
- MIRM $471,794,000.00
- CELC N/A
- Revenue This Year
- MIRM $53.14
- CELC N/A
- Revenue Next Year
- MIRM $19.83
- CELC N/A
- P/E Ratio
- MIRM N/A
- CELC N/A
- Revenue Growth
- MIRM 53.66
- CELC N/A
- 52 Week Low
- MIRM $36.88
- CELC $7.58
- 52 Week High
- MIRM $78.55
- CELC $98.43
- Technical
- Relative Strength Index (RSI)
- MIRM 50.06
- CELC 81.86
- Support Level
- MIRM $68.60
- CELC $86.56
- Resistance Level
- MIRM $73.02
- CELC $96.10
- Average True Range (ATR)
- MIRM 3.10
- CELC 5.08
- MACD
- MIRM 0.08
- CELC 1.14
- Stochastic Oscillator
- MIRM 54.27
- CELC 97.06
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.